Lupin surges as its arm launches AI-powered cardiometabolic wellness platform
Lupin is currently trading at Rs. 1966.00, up by 20.90 points or 1.07% from its previous closing of Rs. 1945.10 on the BSE.
The scrip opened at Rs. 1959.35 and has touched a high and low of Rs. 1966.00 and Rs. 1937.10 respectively. So far 2201 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1972.80 and Rs. 1900.30 respectively. The current market cap of the company is Rs. 88557.61 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.
Lupin’s wholly owned subsidiary -- Lupin Digital Health has launched VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s working professionals reclaim their heart health. Built on the foundation of LYFE - India’s first CDSCO-approved Class C software medical device (SaMD) for critical cardiac conditions - VITALYFE extends hospital-grade cardiac expertise to preventive wellness for its users.
Developed with industry-leading cardiometabolic expertise, VITALYFE uses artificial intelligence, behavioral science, and computer-vision technology to identify early risks and provide personalized, non-medical interventions that address the root causes of heart aging. Available exclusively through insurers, brokers, and employers, the platform enables organizations to integrate cardiometabolic wellness into their health benefits - improving productivity, engagement, and overall well-being while helping insurers reduce lifestyle-related claims.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
